Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Current Leases: 2019-2022

Historic Current Leases for Spyre Therapeutics (SYRE) over the last 4 years, with Dec 2022 value amounting to $625,000.

  • Spyre Therapeutics' Current Leases rose 807.97% to $4.3 million in Q2 2023 from the same period last year, while for Jun 2023 it was $4.3 million, marking a year-over-year increase of 807.97%. This contributed to the annual value of $625,000 for FY2022, which is 43.35% up from last year.
  • Spyre Therapeutics' Current Leases amounted to $625,000 in FY2022, which was up 43.35% from $436,000 recorded in FY2021.
  • In the past 5 years, Spyre Therapeutics' Current Leases ranged from a high of $625,000 in FY2022 and a low of $319,000 during FY2020.
  • Moreover, its 3-year median value for Current Leases was $436,000 (2021), whereas its average is $460,000.
  • Its Current Leases has fluctuated over the past 5 years, first fell by 9.12% in 2020, then soared by 43.35% in 2022.
  • Spyre Therapeutics' Current Leases (Yearly) stood at $351,000 in 2019, then dropped by 9.12% to $319,000 in 2020, then soared by 36.68% to $436,000 in 2021, then spiked by 43.35% to $625,000 in 2022.